Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2017

View Archived Issues

Mast Therapeutics and Savara enter merger agreement

Ramot describes drug conjugates for cancer

Jiangsu Hengrui Medicine patent reports SERDs

Houston Methodist studies tilarginine acetate for triple-negative breast cancer

KemPharm's KP-511 shows promising results in phase I study

Esperion begins pivotal efficacy studies and cardiovascular outcomes study of bempedoic acid

GSK nominates second target under Adaptimmune collaboration

AdAlta reports additional preclinical data for AD-114 in lung and liver fibrosis

Allergan purchases exclusive option right to acquire Lysosomal Therapeutics

Lexicon Pharmaceuticals begins dosing in phase I trial of LX-2761

NeuroGenetic completes phase I studies for Alzheimer's candidate

Taiwan Liposome reports topline results from phase I/II study of TLC-599

First patient treated in phase I study of RG-6016 for SCLC

Bayer patents GLUT-1 inhibitors

Novartis describes SHP-2 inhibitors

Sanofi and ImmuNext to jointly develop INX-021

Actelion Pharmaceuticals reveals NOX4 inhibitors for fibrosis

Apodemus prepares and tests PI4Kbeta inhibitors

Valeant reports positive results from second phase III study of psoriasis drug

Positive phase II results presented for Debio-1450 in patients with ABSSSI

Astellas terminates agreement with UMN Pharma for influenza vaccine programs

Targeting Pol I as a novel therapeutic strategy for preventing arterial restenosis

MRTF inhibition results in marked reduction in lung metastases in RhoC-overexpressing melanoma

Bortezomib as potential new therapeutic option for patient with severe anti-NMDAR encephalitis

SBI Biotech enters agreement with Kyowa Hakko Kirin for SBI-9674

Sarepta signs agreements with Nationwide Children's Hospital for gene therapy programs

FDA approves Egalet's Arymo ER tablets

Mikeluna launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...